High dose biotin causes lab test interference

Biotin is an emerging therapy for the treatment of secondary progressive MS.
Post Reply
User avatar
NHE
Volunteer Moderator
Posts: 5342
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

High dose biotin causes lab test interference

Post by NHE » Thu Sep 26, 2019 2:41 am

If you're taking high-dose biotin then you need to be aware that it will interfere with many medical tests that rely upon biotin/streptavidin immunoassays. This could potentially lead doctors to make incorrect conclusions regarding your health, that in many cases could be critical, e.g. the presence or absence of cancer.

Here is a list presented by Medday of tests which can be distorted by high dose biotin. Note that this list is non-exhaustive and there could be other tests which are not listed, but are still sensitive to biotin interference.

https://medday-lab.com/index.html

Biotin can lead to false low results in sandwich immunoassays.

https://medday-lab.com/sandwishAssays.html

Biotin can lead to false high results in competitive binding immunoassays.

https://medday-lab.com/competitiveAssays.html

Anunymouse
Family Member
Posts: 77
Joined: Thu Sep 04, 2014 10:07 pm

Re: High dose biotin causes lab test interference

Post by Anunymouse » Mon Dec 23, 2019 4:07 am

It definitely throws tsh for thyroid waaaaay off.

User avatar
Petr75
Family Elder
Posts: 604
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic

Re: High dose biotin causes lab test interference

Post by Petr75 » Mon Dec 23, 2019 12:07 pm

2019 Dec 17
Service de Neurologie, CHU Nantes, Nantes, France
High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.
https://www.ncbi.nlm.nih.gov/pubmed/31845825

Abstract
BACKGROUND: A recent controlled trial suggested that high-dose biotin supplementation reverses disability progression in patients with progressive multiple sclerosis.

OBJECTIVE: To analyze the impact of high-dose biotin in routine clinical practice on disability progression at 12 months.

METHODS: Progressive multiple sclerosis patients who started high-dose biotin at Nantes or Rennes Hospital between 3 June 2015 and 15 September 2017 were included in this prospective study. Disability outcome measures, patient-reported outcome measures, relapses, magnetic resonance imaging (MRI) data, and adverse events were collected at baseline, 6, and 12 months.

RESULTS: A total of 178 patients were included. At baseline, patients were 52.0 ± 9.4 years old, mean Expanded Disability Status Scale (EDSS) score was 6.1 ± 1.3, mean disease duration was 16.9 ± 9.5 years. At 12 months, 3.8% of the patients had an improved EDSS score. Regarding the other disability scales, scores either remained stable or increased significantly. In total, 47.4% of the patients described stability, 27.6% felt an improvement, and 25% described a worsening. Four patients (2.2%) had a relapse. Of the 74 patients (41.6%) who underwent an MRI, 20 (27.0%) had new T2 lesions, 8 (10.8%) had gadolinium-enhancing lesions. Twenty-five (14%) reported adverse event.

CONCLUSION: In this study, high-dose biotin did not seem to be associated with a clear improvement in disability.

User avatar
Petr75
Family Elder
Posts: 604
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic

Re: High dose biotin causes lab test interference

Post by Petr75 » Thu Dec 26, 2019 8:39 am

2019 Dec 19
Department of Neurology, Hospital Jacques Monod, Le Havre, France
Tardive Reactivation of Progressive Multiple Sclerosis During Treatment with Biotin.
https://link.springer.com/article/10.10 ... 19-00175-2

Abstract

Multiple sclerosis (MS) is a common autoimmune disease of the central nervous system, causing neurological disability in young adults. A growing understanding of its immunopathogenesis has led to an expanding array of therapies. Notable new advances in disease-modifying therapies for relapsing forms of multiple sclerosis that are based on anti-inflammatory activity have recently been developed. Management of progressive MS is still challenging. Data published in 2014 suggested that daily high doses of biotin, a vitamin involved in myelin synthesis, might have a beneficial impact on disability and progression in progressive MS. However, some patients worsened while on biotin without any clear explanation for this effect. We report the case of a 41-year-old patient suffering from primary progressive (PP) MS who presented after 16 months of treatment with high doses of biotin (QIZENDAY) with worsening of his Expanding Disability Status Scale (EDSS) score and the appearance of a symptomatic new T2 pseudo-tumoural lesion on brain magnetic resonance imaging (MRI), suggestive of tardive inflammatory reactivation possibly due to the biotin. The newer and more effective therapies for MS are, however, associated with risks that necessitate an active management strategy and continuous vigilance. Physicians should be aware of iatrogenic neurological complications and the possible paradoxical effects of biotin. Future treatment approaches to progressive MS must include identification of a biomarker of disease activity. The study of neurofilaments in the cerebrospinal fluid (CSF) and the serum could be of interest when determining the optimal treatment strategy.

Post Reply
  • Similar Topics
    Replies
    Views
    Last post